Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3071-3084

  Cerny Reiterer, Sabine ^a   Rabenhorst, Anja ^b   Stefanzl, Gabriele ^a   Herndlhofer, Susanne ^a   Hoermann, Gregor ^a   Müllauer, Leonhard ^a   Baumgartner, Sigrid ^c   Beham Schmid, Christine ^d   Sperr, Wolfgang R ^a   Mannhalter, Christine ^a   Sill, Heinz ^d   Linkesch, Werner ^d   Arock, Michel ^e   Hartmann, Karin ^b   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e Ecole Normale Superieure de Cachan   (France)

Author keywords

Imatinib; KIT; Mast cell deficiency; Mast cells

Indexed keywords

IMATINIB; MESSENGER RNA; STEM CELL FACTOR; TRYPTASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAST CELL; NONHUMAN; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MAST CELLS; MICE, INBRED BALB C; MICE, INBRED C57BL; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; TIME FACTORS; TREATMENT OUTCOME; TRYPTASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923268845     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3074     Document Type: Article

References (55)

1. Galli SJ. New insights into "the riddle of the mast cells": microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest. 1990; 62:5-33.
2. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol. 1992; 52:333-423.
3. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993; 328:257-265.
4. Taylor ML, Metcalfe DD. Mast cells in allergy and host defense. Allergy Asthma Proc. 2001; 22:115-119.
5. Gurish MF, Austen KF. The diverse roles of mast cells. J Exp Med. 2001; 194:1-5.
6. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005; 23:749-786.
7. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008; 112:946-956.
8. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci. 2008; 49:7-19.
9. Kinet JP, Blank U, Brini A, Jouvin MH, Küster H, Mejan O, Ra C. The high-affinity receptor for immunoglobulin E: a target for therapy of allergic diseases. Int Arch Allergy Appl Immunol. 1991; 94:51-55.
10. Siraganian RP. Mast cell signal transduction from the highaffinity IgE receptor. Curr Opin Immunol. 2003; 15:639-646.
11. Wodnar-Filipowicz A, Heusser CH, Moroni C. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptormediated activation. Nature. 1989; 339:150-152.
12. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature. 1989; 339:64-67.
13. Galli SJ, Wershil BK, Gordon JR, Martin TR. Mast cells: immunologically specific effectors and potential sources of multiple cytokines during IgE-dependent responses. Ciba Found Symp. 1989; 147:53-65.
14. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature. 1990; 346:274-276.
15. Dvorak AM. Subcellular localization of the cytokines, basic fibroblast growth factor and tumor necrosis factor-alpha in mast cells. Chem Immunol Allergy. 2005; 85:72-88.
16. Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S, Füreder W, Bankl HC, Kiener HP, Speiser W, Binder BR, Lechner K, Valent P. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol. 1999; 162:1032-1041.
17. Sillaber C, Baghestanian M, Hofbauer R, Virgolini I, Bankl HC, Füreder W, Agis H, Willheim M, Leimer M, Scheiner O, Binder BR, Kiener HP, et al. Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem. 1997; 272:7824-7832.
18. Valent P, Baghestanian M, Bankl HC, Sillaber C, Sperr WR, Wojta J, Binder BR, Lechner K. New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. Thromb Haemost. 2002; 87:786-790.
19. Bankl HC, Radaszkiewicz T, Klappacher GW, Glogar D, Sperr WR, Grossschmidt K, Bankl H, Lechner K, Valent P. Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand. Circulation. 1995; 91:275-283.
20. Bankl HC, Grossschmidt K, Pikula B, Bankl H, Lechner K, Valent P. Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Hum Pathol. 1999; 30:188-194.
21. Kitamura Y, Taguchi T, Yokoyama M, Inoue M, Yamatodani A, Asano H, Koyama T, Kanamaru A, Hatanaka K, Wershil BK, Galli SJ. Higher susceptibility of mast-cell-deficient W/WV mutant mice to brain thromboembolism and mortality caused by intravenous injection of India ink. Am J Pathol. 1986; 122:469-480.
22. Echtenacher B, Männel DN, Hültner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381:75-77.
23. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature. 1996; 381:77-80.
24. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978; 52:447-452.
25. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood. 1979; 53:492-497.
26. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992; 80:2237-2245.
27. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol. 1992; 148:772-777.
28. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today. 1994; 15:111-114.
29. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol. 1993; 142:965-974.
30. Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol. 1991; 147:4224-4228.
31. Födinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, Valent P, Mannhalter C. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood. 1994; 84:2954-2959.
32. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004.
33. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355:2408-2417.
34. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005; 105:2640-2653.
35. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112:4808-4817.
36. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004; 103:2879-2891.
37. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002; 38:19-27.
38. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H, Amano K, Tokiwa T, Mitsui H, Saito H, Iikura Y, Ishizaka T, Nakahata T. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood. 1995; 86:3705-3714.
39. Saito H, Ebisawa M, Sakaguchi N, Onda T, Iikura Y, Yanagida M, Uzumaki H, Nakahata T. Characterization of cord-blood-derived human mast cells cultured in the presence of Steel factor and interleukin-6. Int Arch Allergy Immunol. 1995; 107:63-65
40. Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Iikura Y, Awaji T, Tsujimoto G, Yanagida M, Uzumaki H, Takahashi G, Tsuji K, et al. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol. 1996; 157:343-350.
41. Agis H, Willheim M, Sperr WR, Wilfing A, Krömer E, Kabrna E, Spanblöchl E, Strobl H, Geissler K, Spittler A, Boltz-Nitulescu G, Majdic O, Lechner K, et al. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol. 1993; 151:4221-4227.
42. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995; 96:2702-2710.
43. Kanthawatana S, Carias K, Arnaout R, Hu J, Irani AM, Schwartz LB. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol. 1999; 103:1092-1099.
44. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Semper H, Simonitsch-Klupp I, Horny HP, Valent P. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002; 128:136-141.
45. Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F, Baghestanian M, Rezaie-Majd A, Sperr WR, Lechner K, Valent P. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood. 2001; 98:2580-2583.
46. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, Endler G, Rumpold H, Agis H, Sillaber C, Jäger U, Valent P. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest. 2009; 39:914-923.
47. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100:2292-2302.
48. Valent P, Sperr WR, Sotlar K, Reiter A, Akin C, Gotlib J, Horny HP, Arock M. The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol. 2014; 7:683-690.
49. Cattoretti G, Pileri S, Parravicini C, Becker MH, Poggi S, Bifulco C, Key G, D'Amato L, Sabattini E, Feudale E, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993; 171:83-98.
50. Jordan JH, Walchshofer S, Jurecka W, Mosberger I, Sperr WR, Wolff K, Chott A, Bühring HJ, Lechner K, Horny HP, Valent P. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol. 2001; 32:545-552.
51. Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R, Kerenyi M, Boudot C, Gouilleux F, Kornfeld JW, Sillaber C, Moriggl R, Valent P. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009; 175:2416-2429.
52. Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls AF, Mayerhofer M, Valent P. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1- independent disease progression. Neoplasia. 2012; 14:572-584.
53. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37.
54. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res. 2009; 127:1-4.
55. Level B. A high sampling rate automated continuous flow fluorometric technique for the analysis of nanogram (ng) levels of histamine in biological samples. Anal Biochem. 1983; 133:16-29.